RELY-ABLE® Study Demonstrates Benefits of Pradaxa® (Dabigatran Etexilate) Are Maintained for over Four Years

RELY-ABLE® Study Demonstrates Benefits of Pradaxa® (Dabigatran Etexilate) Are Maintained for over Four Years PR Newswire BRACKNELL, England, November 8, 2012 BRACKNELL, England, November 8, 2012 /PRNewswire/ -- Pradaxa® (dabigatran etexilate) is the first and only novel oral anticoagulant supported by long-term clinical data of 4.3 years' duration Benefits for both doses shown to be sustained throughout study duration, providing evidence of long term efficacy and safety New data from the RELY-ABLE® study have provided additional support to the safety profile and efficacy of Pradaxa® (dabigatran etexilate) for stroke prevention in patients with nonvalvular atrial fibrillation (AF) over a period in excess of 2 [*][1]years. The new long-term results presented at the American Heart Association's (AHA) Scientific Sessions, are [†]consistent with the findings from the landmark RE-LY® trial . The rates of stroke and haemorrhage observed during an additional 2.3 years of blinded follow-up in RELY-ABLE® correspond to the initial RE-LY® results, with the benefit of [1]-[3]both doses of dabigatran etexilate sustained throughout the study duration. The combined data from RE-LY® and RELY-ABLE® provides over four years of clinical trial experience and constitutes the longest evaluation of the benefits and safety of any novel oral anticoagulant for stroke prevention in AF to date.